Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

A mixture model of ductus venosus pulsatility index in screening for aneuploidies at 11-13 weeks' gestation.

Maiz N, Wright D, Ferreira AF, Syngelaki A, Nicolaides KH.

Fetal Diagn Ther. 2012;31(4):221-9. doi: 10.1159/000337322. Epub 2012 May 17.

PMID:
22614037
2.

Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.

Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.

Ultrasound Obstet Gynecol. 2006 Feb;27(2):151-5.

3.

Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.

Karadzov-Orlić N, Egić A, Filimonović D, Marinković M, Damnjanović-Pazin B, Milovanović Z, Joksić I, Branković S, Lukić R, Mandić V, Cerović N, Mojović D, Plamenac S, Stanković M, Maglić D, Mikovć Z.

Srp Arh Celok Lek. 2012 Sep-Oct;140(9-10):606-11.

4.

Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.

Soergel P, Pruggmayer M, Schwerdtfeger R, Muhlhaus K, Scharf A.

Fetal Diagn Ther. 2006;21(3):264-8.

PMID:
16601335
5.

Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.

Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.

Ultrasound Obstet Gynecol. 2008 Sep;32(4):488-92. doi: 10.1002/uog.6123.

6.

Prospective validation of first-trimester combined screening for trisomy 21.

Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH.

Ultrasound Obstet Gynecol. 2009 Jul;34(1):14-8. doi: 10.1002/uog.6412.

8.

First- and second-trimester screening: detection of aneuploidies other than Down syndrome.

Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Tripp T, Bianchi DW, D'Alton ME; First and Second Trimester Evaluation of Risk (FASTER) Research Consortium.

Obstet Gynecol. 2007 Sep;110(3):651-7.

PMID:
17766613
9.

First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.

Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH.

Fetal Diagn Ther. 2014;35(2):118-26. doi: 10.1159/000357430. Epub 2013 Dec 18.

PMID:
24356462
10.

Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy.

Brizot ML, Snijders RJ, Butler J, Bersinger NA, Nicolaides KH.

Br J Obstet Gynaecol. 1995 Feb;102(2):127-32. Review.

PMID:
7538782
11.

Screening for fetal aneuploidies at 11 to 13 weeks.

Nicolaides KH.

Prenat Diagn. 2011 Jan;31(1):7-15. doi: 10.1002/pd.2637. Review.

PMID:
21210475
12.

First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.

Kagan KO, Wright D, Nicolaides KH.

Ultrasound Obstet Gynecol. 2015 Jan;45(1):42-7. doi: 10.1002/uog.14691. Epub 2014 Nov 28.

13.

Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.

Borenstein M, Persico N, Kagan KO, Gazzoni A, Nicolaides KH.

Ultrasound Obstet Gynecol. 2008 Jul;32(1):5-11. doi: 10.1002/uog.5334.

14.

First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.

Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.

Ultrasound Obstet Gynecol. 2013 Jul;42(1):41-50. doi: 10.1002/uog.12511. Epub 2013 Jun 7.

15.

First-trimester screening for trisomy 21 using alpha-fetoprotein.

Bredaki FE, Wright D, Matos P, Syngelaki A, Nicolaides KH.

Fetal Diagn Ther. 2011;30(3):215-8. doi: 10.1159/000330198. Epub 2011 Sep 23.

PMID:
21952001
16.

One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.

Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH.

Ultrasound Obstet Gynecol. 2002 Sep;20(3):219-25.

17.

First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.

Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH.

Ultrasound Obstet Gynecol. 2008 May;31(5):493-502. doi: 10.1002/uog.5332.

18.

Temporal effect of Afro-Caribbean race on serum pregnancy-associated plasma protein-a at 9-13 weeks' gestation in screening for aneuploidies.

Ball S, Wright D, Sodre D, Lachmann R, Nicolaides KH.

Fetal Diagn Ther. 2012;31(3):162-9. doi: 10.1159/000336252. Epub 2012 Feb 25.

PMID:
22377654
19.

Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.

Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH.

Ultrasound Obstet Gynecol. 2009 Mar;33(3):259-64. doi: 10.1002/uog.6318.

20.

Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.

Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.

Hum Reprod. 2008 Sep;23(9):1968-75. doi: 10.1093/humrep/den224. Epub 2008 Jun 10.

PMID:
18544579

Supplemental Content

Support Center